Introduction: Malaria remains a significant public health challenge globally, particularly in sub-Saharan Africa, where progress has stalled in recent years. Long-lasting insecticidal nets (LLINs) are a critical preventive tool against malaria. This study investigated the effectiveness of newer-generation LLINs following a universal coverage campaign in Uganda.
View Article and Find Full Text PDFPLOS Glob Public Health
February 2025
Long-lasting insecticidal nets (LLINs) are the cornerstone of malaria control, but their effectiveness is threatened by pyrethroid resistance. We embedded a pragmatic, cluster-randomised trial into Uganda's national LLIN distribution campaign in 2020-2021, comparing pyrethroid-piperonyl butoxide (PBO) LLINs to pyrethroid-pyriproxyfen LLINs. Target communities surrounding public health facilities (clusters, n=64), covering 32 districts were included.
View Article and Find Full Text PDFA fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations. At an extended 3.
View Article and Find Full Text PDFContext: Patients with advanced cancer discharged from the hospital with no plan for further disease-directed treatment (on 'best supportive care'; BSC) and without specialized palliative care at home are extremely vulnerable to end-of-life suffering and hospital readmission.
Objectives: To assess preliminary outcomes of PATHS (Post-Acute Transition to Home with Supportive Care), a nurse practitioner-led telehealth intervention delivering proactive, intensive, specialized palliative care in the immediate two-week post-discharge period.
Methods: We conducted a single-arm prospective quality improvement evaluation of PATHS with patients ≥21 years with advanced solid tumor malignancies discharged from the hospital on BSC having initially declined hospice.
Importance: Two interventions to prevent severe respiratory syncytial virus (RSV) in infants were approved in 2023-a bivalent prenatal RSV prefusion F protein-based (RSVpreF) vaccine and an infant monoclonal antibody (nirsevimab). Understanding their uptake and clinical outcomes is essential for public health planning.
Objective: To describe uptake of the prenatal RSVpreF vaccine and infant nirsevimab.